pubmed-article:6891320 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:6891320 | lifeskim:mentions | umls-concept:C0021467 | lld:lifeskim |
pubmed-article:6891320 | lifeskim:mentions | umls-concept:C1149501 | lld:lifeskim |
pubmed-article:6891320 | lifeskim:mentions | umls-concept:C0021469 | lld:lifeskim |
pubmed-article:6891320 | lifeskim:mentions | umls-concept:C0031586 | lld:lifeskim |
pubmed-article:6891320 | pubmed:issue | 2 | lld:pubmed |
pubmed-article:6891320 | pubmed:dateCreated | 1983-3-17 | lld:pubmed |
pubmed-article:6891320 | pubmed:abstractText | Phorbol esters inhibit the binding of insulin to its receptors on U-937 monocyte-like and HL-60 promyelocytic leukemia human cell lines. Within 20-30 min, exposure of these cells to 12-O-tetradecanoylphorbol 13-acetate (TPA) at 37 degrees C results in a 50% reduction of the specific binding of 125I-insulin. Half-maximal inhibition occurs at 1 nM TPA. Other tumor-promoting phorbol esters also inhibit 125I-insulin binding in a dose-dependent manner which parallels their known promoting activity in vivo. TPA does not alter the degradation of the hormone nor does it induce any shedding of its receptors in the medium. The effect of phorbol esters is dependent on temperature and cell type. It is less prominent at 22 degrees C than at 37 degrees C. It is reversible within 2 h at 37 degrees C. TPA reduces the binding of insulin predominantly by increasing its dissociation rate. This effect results in an accelerated turnover of the hormone on its receptors. | lld:pubmed |
pubmed-article:6891320 | pubmed:language | eng | lld:pubmed |
pubmed-article:6891320 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:6891320 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:6891320 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:6891320 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:6891320 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:6891320 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:6891320 | pubmed:month | Dec | lld:pubmed |
pubmed-article:6891320 | pubmed:issn | 0014-2956 | lld:pubmed |
pubmed-article:6891320 | pubmed:author | pubmed-author:ThomopoulosPP | lld:pubmed |
pubmed-article:6891320 | pubmed:author | pubmed-author:TestaUU | lld:pubmed |
pubmed-article:6891320 | pubmed:author | pubmed-author:GourdinM FMF | lld:pubmed |
pubmed-article:6891320 | pubmed:author | pubmed-author:VainchenkerWW | lld:pubmed |
pubmed-article:6891320 | pubmed:author | pubmed-author:TiteuxMM | lld:pubmed |
pubmed-article:6891320 | pubmed:author | pubmed-author:Hertz | lld:pubmed |
pubmed-article:6891320 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:6891320 | pubmed:day | 15 | lld:pubmed |
pubmed-article:6891320 | pubmed:volume | 129 | lld:pubmed |
pubmed-article:6891320 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:6891320 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:6891320 | pubmed:pagination | 389-93 | lld:pubmed |
pubmed-article:6891320 | pubmed:dateRevised | 2009-11-19 | lld:pubmed |
pubmed-article:6891320 | pubmed:meshHeading | pubmed-meshheading:6891320-... | lld:pubmed |
pubmed-article:6891320 | pubmed:meshHeading | pubmed-meshheading:6891320-... | lld:pubmed |
pubmed-article:6891320 | pubmed:meshHeading | pubmed-meshheading:6891320-... | lld:pubmed |
pubmed-article:6891320 | pubmed:meshHeading | pubmed-meshheading:6891320-... | lld:pubmed |
pubmed-article:6891320 | pubmed:meshHeading | pubmed-meshheading:6891320-... | lld:pubmed |
pubmed-article:6891320 | pubmed:meshHeading | pubmed-meshheading:6891320-... | lld:pubmed |
pubmed-article:6891320 | pubmed:meshHeading | pubmed-meshheading:6891320-... | lld:pubmed |
pubmed-article:6891320 | pubmed:meshHeading | pubmed-meshheading:6891320-... | lld:pubmed |
pubmed-article:6891320 | pubmed:year | 1982 | lld:pubmed |
pubmed-article:6891320 | pubmed:articleTitle | Inhibition of insulin receptor binding by phorbol esters. | lld:pubmed |
pubmed-article:6891320 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:6891320 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6891320 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6891320 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6891320 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6891320 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6891320 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6891320 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6891320 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6891320 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6891320 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6891320 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6891320 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6891320 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6891320 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6891320 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6891320 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6891320 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6891320 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6891320 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6891320 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6891320 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6891320 | lld:pubmed |